Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes
Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressmen H, Damsker JM, McCall JM.Hoffman,E.P.,Steroids(2018),htps://doi.org/10.1016/j.steroids.2018.02.010
Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy
J. Burakiewicz , C. Sinclair, D. Fischer, G. Walter, H. Kan, K. Hollingsworth. J Neurol (2017) 264:2053–2067 DOI 10.1007/s00415-017-8547-3
A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone.
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice.
VBP15: preclinical characterisation of a novel anti-inflammatory delta 9,11 steroid.
Large-scale serum protein biomarker discovery in Duchenne muscular dystophy